Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Ke · SciRah

Researcher profile · Semantic Scholar

C. Ke

Share profile

C. Ke — researcher profile on SciRah

h-index: 9
Works: 28
Citations: 2,103

Most-cited papers

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
M. Smith, B. Egerdie, Narciso Hernández Toriz, R. Feldman +8 more
2009New England Journal of Medicine1,003 citations Open access
Semantic Scholar
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
A. Lipton, K. Fizazi, A. Stopeck, D. Henry +15 more
2012European Journal of Cancer570 citations
Semantic Scholar
Sarcopenia during androgen-deprivation therapy for prostate cancer.
M. Smith, F. Saad, B. Egerdie, P. Sieber +4 more
2012Journal of Clinical Oncology181 citations Open access
Semantic Scholar
Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
M. Smith, F. Saad, B. Egerdie, M. Szwedowski +4 more
2009Journal of Urology114 citations Open access
Semantic Scholar
Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases
B. Dixon, L. Greenbaum, Liwei Huang, S. Rajan +3 more
2023Kidney International Reports93 citations Open access
Semantic Scholar
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
V. Beynon, I. George, C. Elliott, D. Arnold +11 more
2022BMJ Neurology Open40 citations Open access
Semantic Scholar
Denosumab and Changes in Bone Turnover Markers During Androgen Deprivation Therapy for Prostate Cancer
Matthew R. Smith, F. Saad, B. Egerdie, P. Sieber +4 more
2011Journal of Bone and Mineral Research35 citations Open access
Semantic Scholar
Responder Analysis of the Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
B. Egerdie, F. Saad, M. Smith, T. Tammela +6 more
2012Prostate Cancer and Prostatic Diseases20 citations Open access
Semantic Scholar
648 BENEFIT OF DENOSUMAB THERAPY IN PATIENTS WITH BONE METASTASES FROM CASTRATE RESISTANT PROSTATE CANCER: A NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS
K. Miller, K. Fizazi, M. Smith, Jose Pablo Moroto +7 more
201110 citations
Semantic Scholar
Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC).
F. Saad, M. Smith, B. Egerdie, T. Tammela +6 more
2009Journal of Clinical Oncology8 citations
Semantic Scholar
A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases.
A. Lipton, A. Stopeck, R. von Moos, D. Henry +6 more
20106 citations
Semantic Scholar
Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial
R. Coleman, C. Barrios, R. Bell, D. Finkelstein +6 more
20123 citations Open access
Semantic Scholar
3061 POSTER Prevention of Skeletal-Related Events With Denosumab or Zoledronic Acid – Combined Analysis From 3 Registrational Trials
A. Lipton, K. Fizazi, A. Stopeck, D. Henry +6 more
20113 citations
Semantic Scholar
Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy.
M. Smith, G. Ellis, F. Saad, T. Tammela +6 more
2009Journal of Clinical Oncology3 citations
Semantic Scholar
7005 Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
M. Smith, B. Egerdie, P. Sieber, T. Tammela +5 more
20093 citations
Semantic Scholar
Abstract OT2-3-03: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase 3 clinical trial
P. Goss, C. Barrios, A. Chan, D. Finkelstein +6 more
20122 citations
Semantic Scholar
Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.
P. Goss, C. Barrios, R. Bell, D. Finkelstein +6 more
20122 citations
Semantic Scholar
OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE).
P. Goss, C. Barrios, R. Bell, D. Finkelstein +8 more
20112 citations
Semantic Scholar
846 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DENOSUMAB IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER
M. Smith, B. Egerdie, T. Hernández, R. Feldman +8 more
20092 citations
Semantic Scholar
EFFECTS OF TWICE-YEARLY SUBCUTANEOUS DENOSUMAB ON BONE MINERAL DENSITY IN MEN RECEIVING ANDROGEN-DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER
M. Smith, B. Egerdie, M. Szwedowski, C. Ke +2 more
20092 citations
Semantic Scholar
Risk reduction for vertebral fractures in patients with normal to osteopenic bone mineral density receiving denosumab
K. Lippuner, J. Wolff, P. Hadji, A. Braun +3 more
20141 citations
Semantic Scholar
AOS13 Denosumab versus zoledronic acid for the prevention of skeletal-related events in patients with bone metastases secondary to solid tumours: An integrated analysis of three phase 3 studies
A. Stopeck, G. Richardson, S. Siena, A. Lipton +6 more
20121 citations
Semantic Scholar
Denosumab versus zoledronic acid (ZA) for the treatment of bone metastases: An integrated analysis of results from 2 randomized, double-blind, phase 3 trials
A. Lipton, A. Stopeck, R. von Moos, D. Henry +6 more
20111 citations
Semantic Scholar
A RESPONDER ANALYSIS OF THE EFFECTS OF DENOSUMAB ON BONE MINERAL DENSITY IN MEN WITH PROSTATE CANCER RECEIVING ANDROGEN DEPRIVATION THERAPY
B. Egerdie, M. Smith, T. Tammela, F. Saad +3 more
20091 citations
Semantic Scholar
Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy
Matthew R. Smith, G. Ellis, F. Saad, T. Tammela +6 more
20160 citations
Semantic Scholar
Selected Abstracts presented at the XIII Symposium of the International Society of Oncology Pharmacy Practitioners, 9–11 May 2012, Melbourne, Australia
M. Smith, S. Oudard, L. Karsh, B. Egerdie +24 more
2012Journal of Oncology Pharmacy Practice0 citations
Semantic Scholar
132 SARCOPENIA IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY (ADT) FOR PROSTATE CANCER: A PROSPECTIVE 3-YEAR STUDY
M. Smith, F. Saad, B. Egerdie, P. Sieber +5 more
20100 citations
Semantic Scholar
NATURAL HISTORY OF BONE LOSS IN MEN WITH PROSTATE CANCER RECEIVING ANDROGEN-DEPRIVATION THERAPY
F. Saad, R. Feldman, J. Heracek, C. Ke +1 more
20090 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Saad×15
Invite
F. Saad — researcher profile on SciRah
C. Goessl×15
Invite
C. Goessl — researcher profile on SciRah
B. Egerdie×13
Invite
B. Egerdie — researcher profile on SciRah
T. Tammela×12
Invite
T. Tammela — researcher profile on SciRah

×9

Invite

B. Leder — researcher profile on SciRah

Invite

R. Dansey — researcher profile on SciRah

Invite

M. Smith — researcher profile on SciRah

Invite

A. Braun — researcher profile on SciRah

M. Szwedowski×5

Invite

M. Szwedowski — researcher profile on SciRah

Invite

A. Lipton — researcher profile on SciRah

Invite

K. Fizazi — researcher profile on SciRah

Invite

A. Stopeck — researcher profile on SciRah